BioScrip Reports First Quarter 2019 Financial Results DENVER, CO

BioScrip Reports First Quarter 2019 Financial

DENVER, CO, May 2, 2019 - BioScrip,

Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and

home care management solutions, today announced its first quarter 2019 financial results.

First Quarter 2019 Highlights

Daniel E. Greenleaf, President and Chief

Executive Officer, commented, "BioScrip delivered net revenue growth of 7.8% on a billing day rate basis in the first quarter

of 2019. This is the third consecutive quarter of comparable net revenue growth for BioScrip, and we are confident this trend will

continue. Adjusted EBITDA increased 25.6% year over year, to $7.1 million, despite $4.5 million of higher bad debt expense in the

quarter, and was in line with our internal expectations. We continue to make progress in improving our cash collections and expect

that bad debt expense as a percent of sales will improve."

Mr. Greenleaf continued, "The

merger transaction with Option Care continues to proceed on plan, and we filed the preliminary merger proxy statement earlier

this week, highlighting the earnings power of the pro forma combined company. We remain incredibly enthusiastic about

the strategic and financial virtues of this combination, which will create the nation's leading independent national

provider of home infusion services."

Financial Guidance and Conference

Given the pending combination with Option

Care, the Company will not be providing BioScrip financial guidance and will not be hosting a quarterly conference call. The Company

and Option Care intend to conduct investor and analyst meetings in the coming days. An updated investor presentation to be used

in these meetings will be filed today with the U.S. Securities and Exchange Commission ("SEC") and available on the

ADDITIONAL INFORMATION AND WHERE

On April 30, 2019, BioScrip, Inc. ("BioScrip"

or the "Company") filed with the Securities and Exchange Commission ("SEC") a preliminary proxy statement

in connection with the proposed transaction. The definitive proxy statement will be sent to the stockholders of BioScrip and will

contain important information about the proposed transaction and related matters. INVESTORS AND SECURITY HOLDERS ARE URGED AND

ADVISED TO READ THE PRELIMINARY PROXY STATEMENT AND THE DEFINITIVE PROXY STATEMENT WHEN IT BECOMES AVAILABLE BECAUSE IT WILL CONTAIN

IMPORTANT INFORMATION. The proxy statement and other relevant materials (when they become available) and any other documents filed

by the Company with the SEC may be obtained free of charge at the SEC's website, at www.sec.gov. In addition, security holders

will be able to obtain free copies of the proxy statement and other relevant materials from the Company by contacting Investor

Relations by mail at 1600 Broadway, Suite 700, Denver, CO 80202, Attn: Investor Relations, by telephone at (720) 697-5200, or

by going to the Company's Investor Relations page on its corporate web site at https://investors.bioscrip.com.

PARTICIPANTS IN THE SOLICITATION

The Company and its directors and executive

officers may be deemed to be participants in the solicitation of proxies from stockholders in connection with the matters discussed

above. Information about the Company's directors and executive officers is set forth in the Proxy Statement on Schedule 14A

for the Company's 2019 annual meeting of stockholders, which was filed with the SEC on April 30, 2019. This document can

be obtained free of charge from the sources indicated above. Information regarding the ownership of the Company's directors

and executive officers in the Company's securities is included in the Company's SEC filings on Forms 3, 4, and 5, which

can be found through the SEC's website at www.sec.gov. Other information regarding the participants in the proxy solicitation

and a description of their direct and indirect interests, by security holdings or otherwise, is contained in the preliminary proxy

statement and will be contained in the definitive proxy statement and other relevant materials to be filed with the SEC when they

About BioScrip, Inc.

BioScrip, Inc. is the largest independent

national provider of infusion and home care management solutions, with approximately 2,100 teammates and nearly 70 service locations

across the U.S. BioScrip partners with physicians, hospital systems, payors, pharmaceutical manufacturers and skilled nursing facilities

to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy

and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum

of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer

service, and values that promote positive outcomes and an enhanced quality of life for those it serves.

Forward-Looking Statements -

This communication, in addition to historical

information, contains "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995)

regarding, among other things, future events or the future financial performance of BioScrip and Option Care. All statements other

than statements of historical facts are forward-looking statements. In addition, words such as "anticipate," "believe,"

"contemplate," "continue," "could," "estimate," "expect," "intend,"

"may," "plan," "potential," "predict," "project," "seek,"

"should," "target," "will," "would," or the negative of these words, and words

and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking

statements. Forward-looking statements relating to the proposed transaction include, but are not limited to: statements about the

benefits of the proposed transaction between BioScrip and Option Care, including future financial and operating results; expected

synergies; BioScrip's and Option Cares plans, objectives, expectations and intentions; the expected timing of completion

of the proposed transaction; and other statements relating to the acquisition that are not historical facts. Forward-looking statements

are based on information currently available to BioScrip and Option Care and involve estimates, expectations and projections. Investors

are cautioned that all such forward-looking statements are subject to risks and uncertainties (both known and unknown), and many

factors could cause actual events or results to differ materially from those indicated by such forward-looking statements. With

respect to the proposed transaction between BioScrip and Option Care, these factors could include, but are not limited to: the

risk that BioScrip or Option Care may be unable to obtain governmental and regulatory approvals required for the transaction, or

that required governmental and regulatory approvals may delay the transaction or result in the imposition of conditions that could

reduce the anticipated benefits from the proposed transaction or cause the parties to abandon the proposed transaction; the risk

that a condition to closing of the transaction may not be satisfied; the length of time necessary to consummate the proposed transaction,

which may be longer than anticipated for various reasons; the risk that the businesses will not be integrated successfully; the

risk that the cost savings, synergies and growth from the proposed transaction may not be fully realized or may take longer to

realize than expected; the diversion of management time on transaction-related issues; the effect of future regulatory or legislative

actions on the companies or the industries in which they operate; the risk that the credit ratings of the combined company or its

subsidiaries may be different from what the companies expect; economic and foreign exchange rate volatility; and the other risks

contained in BioScrip's most recently filed Annual Report on Form 10-K.

Many of these risks, uncertainties and

assumptions are beyond BioScrip's ability to control or predict. Because of these risks, uncertainties and assumptions, you

should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the

information currently available to the parties on the date they are made, and neither BioScrip nor Option Care undertakes any obligation

to update publicly or revise any forward-looking statements to reflect events or circumstances that may arise after the date of

this communication. Nothing in this communication is intended, or is to be construed, as a profit forecast or to be interpreted

to mean that earnings per BioScrip share for the current or any future financial years or those of the combined company, will necessarily

match or exceed the historical published earnings per BioScrip share, as applicable. Neither BioScrip nor Option Care gives any

assurance (1) that either BioScrip or Option Care will achieve its expectations, or (2) concerning any result or the timing thereof,

in each case, with respect to any regulatory action, administrative proceedings, government investigations, litigation, warning

letters, consent decrees, cost reductions, business strategies, earnings or revenue trends or future financial results. All subsequent

written and oral forward-looking statements concerning BioScrip, Option Care, the proposed transaction, the combined company or

other matters and attributable to BioScrip or Option Care or any person acting on their behalf are expressly qualified in their

entirety by the cautionary statements above.

Note Regarding Use of Non-GAAP Financial

In addition to reporting financial information

in accordance with generally accepted accounting principles (GAAP), the Company is also reporting Adjusted EBITDA, which is a non-GAAP

financial measure. Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be used in isolation

or as a substitute or alternative to net income, operating income or any other performance measure derived in accordance with GAAP,

or as a substitute or alternative to cash flow from operating activities or a measure of the Company's liquidity. In addition,

the Company's definition of Adjusted EBITDA may not be comparable to similarly titled non-GAAP financial measures reported by other

companies. Adjusted EBITDA, as defined by the Company, represents net income before net interest expense, income tax expense, depreciation